Ocular Hypertension News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

HHV-1, -2, -3: Precise medical management of herpetic nodular anterior scleritis - ModernMedicine



HHV-1, -2, -3: Precise medical management of herpetic nodular anterior scleritis 
ModernMedicine
Secondary ocular hypertension of the treated eye was being managed with twice-daily topical dorzolamide. Ophthalmic history was negative for surgeries or conditions except cataracts. He reported multiple tick bites about 8 to 10 years ago, and denied ...

 


Why Is Aerie (AERI) Down 5.9% Since the Last Earnings Report? - Nasdaq



Why Is Aerie (AERI) Down 5.9% Since the Last Earnings Report? 
Nasdaq
On Oct 13, the Dermatologic and Ophthalmic Drugs Advisory Committee of the FDA voted in favor of Rhopressa's approval. The members of the committee unanimously agreed that the trials support the efficacy of netarsudil ophthalmic solution for reducing ...
Aerie Pharmaceuticals (NASDAQ:AERI) & Its Rivals Head to Head Comparison StockNewsTimes
A Reversal for Aerie Pharmaceuticals, Inc. (AERI) Is Not Near. The Stock Rises Again Weekly Register
Macquarie Group Ltd. Increases Stake in Aerie Pharmaceuticals Inc (AERI) Newburgh Gazette
Zacks.com  -Zacks Investment Research  -Barchart.com  -Finviz 
all 65 news articles » 


Intraocular pressure 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension - Dove Medical Press



Intraocular pressure 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension 
Dove Medical Press
Objective: The aim of this study was to investigate the incidence, risk factors, and treatment of elevated intraocular pressure (IOP) 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension. Patients and methods: This ...

 


Ocular Therapeutix? to Participate in the Guggenheim Securities 5 - Business Wire (press release)



UtahHerald.com
 
Ocular Therapeutix? to Participate in the Guggenheim Securities 5 
Business Wire (press release)
Ocular Therapeutix's lead product candidate, DEXTENZA? (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP ...
Analyzing CR Bard (BCR) & Ocular Therapeutix (OCUL) StockNewsTimes

all 13 news articles » 


Vyzulta approval tops November Glaucoma news - Healio



Vyzulta approval tops November Glaucoma news 
Healio
Vyzulta (latanoprostene bunod ophthalmic solution, 0.024%) is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. It is the first prostaglandin analog to have nitric oxide as one of its metabolites. Read more ...

 


November approvals lead FDA activity in ophthalmology - Healio



November approvals lead FDA activity in ophthalmology 
Healio
The Light Adjustable Lens with the Light Delivery Device from RxSight is the first medical device system that can make adjustments to lens power after cataract surgery. Read more here. 2. FDA gives nod to Bausch + Lomb's once-daily glaucoma drops ...

 


Head-To-Head Review: CR Bard (BCR) and Ocular Therapeutix (OCUL) - Week Herald



Press Telegraph
 
Head-To-Head Review: CR Bard (BCR) and Ocular Therapeutix (OCUL) 
Week Herald
Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase ...
Zacks' 7 Best Strong Buys for 2018 Zacks.com

all 20 news articles » 


Ocular Hypertension Market Research Report Pipeline Review H1 Assessment by Mechanism of Action, Drug Profile ... - MilTech



Ocular Hypertension Market Research Report Pipeline Review H1 Assessment by Mechanism of Action, Drug Profile ... 
MilTech
Ocular Hypertension Market Pipeline Review, H1 analysis report speaks about key players with pipeline review and targeted therapeutics covering drugs profile, Symptoms and Treatment includes of Ocular Hypertension industry. The report delivers ...

and more » 


Single bimatoprost implant controls IOP at 2 years in some patients - Healio



Single bimatoprost implant controls IOP at 2 years in some patients 
Healio
NEW ORLEANS ? All doses and strengths of Allergan's bimatoprost sustained release implant demonstrated efficacy in patients with open-angle glaucoma, E. Randy Craven, MD, said at the American Academy of Ophthalmology meeting. Craven gave 24-month ...

 


Financial Contrast: Ocular Therapeutix (OCUL) vs. Capnia (SLNO) - StockNewsTimes



Financial Contrast: Ocular Therapeutix (OCUL) vs. Capnia (SLNO) 
StockNewsTimes
Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase ...

and more »